Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
Clinical trial NCT04556669 · UNKNOWN
Trial details
- NCT number
- NCT04556669
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-01
- Primary completion
- 2023-08-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.